iFAST Diagnostics Secures £5 Million Investment
iFAST Diagnostics, a UK-based biotech firm specializing in rapid infection testing technology, has successfully raised £5 million in an equity funding round. This investment aims to propel the development and expansion of their rapid antimicrobial susceptibility testing (AST) technology.
Investment Details
The funding round, announced on May 28, 2026, was led by Meridian Health Ventures. Other investors include QantX, RAW Ventures, OKG Capital, and members of Cambridge Capital Group. These investors have shown continued confidence in iFAST Diagnostics' innovative approach to infection testing.
Company Overview
Under the leadership of Chief Executive Officer Toby King, iFAST Diagnostics focuses on the growing $4 billion market for antimicrobial susceptibility testing. Their cutting-edge technology offers rapid results, capable of delivering outcomes in under three hours from a positive blood culture and within three to four hours from a raw urine sample.
Strategic Use of Funds
The newly acquired funds will be strategically utilized to expand iFAST Diagnostics' operations within the UK, seek EU regulatory approval, and further the advancement of their clinical research. This move is expected to enhance treatment decisions and improve patient outcomes by providing faster and more reliable testing solutions.
Addressing Antimicrobial Resistance
iFAST Diagnostics aims to play a crucial role in combating antimicrobial resistance. By offering rapid and accurate testing, the company seeks to support healthcare providers in making informed treatment decisions, ultimately improving patient care and outcomes.
This latest round of funding marks a significant milestone for iFAST Diagnostics as it continues to innovate and expand its reach in the healthcare sector.